期刊文献+

声脉冲辐射力弹性成像技术评价乳腺癌新辅助化疗疗效的初步探讨 被引量:3

The preliminary research of the evaluation of ARFI technology in the efficacy of neoadjuvant chemotherapy for breast carcinoma
下载PDF
导出
摘要 目的探讨声脉冲辐射力弹性成像(acoustic radiation force impulse imaging,ARFI)技术在乳腺癌新辅助化疗疗效评价中的应用价值。方法对2012年12月至2013年12月间我院经病理学证实的60例乳腺癌患者应用声脉冲辐射力成像技术,分别测量新辅助化疗前后肿瘤内部组织的横向剪切波速度(shear wave velocity,SWV),分析其化疗前后的变化,并与病理结果结合对照研究。结果新辅助化疗前后肿瘤组织的SWV变化差异有统计学意义,应用ARFI技术评价乳腺癌新辅助化疗疗效,ARFI技术评价的特异度、灵敏度分别为85.7%、89.1%,ARFI技术评价的总有效率为71.7%,ARFI技术评价与病理学评价比较,两者差异无统计学意义。结论 ARFI技术为乳腺癌新辅助化疗的疗效评价提供了定量的影像学评价方法,能对乳腺癌新辅助化疗的疗效做出客观评价,具有一定的临床应用价值。 Objective To explore the application values of ARFI (acoustic radiation force impulse imaging) technology in evaluating effect of neoadjuvant chemotherapy for breast carcinoma. Methods 60 patients who went to our hospital for physical examinations during 2012 December to 2013 December were enrolled in the research. And every lesion was measured the transverse shear wave velocity of the interior tumor around the neoadjuvant chemotherapy(NAC) ,and compared with the pathological results. Results There were significant differences in SWV changes in tumor tissue before and after NAC. The NAC of ARFI technology in evaluating breast cancer specific ARFI technology evaluation, the sensitivity and respectively of the application values of ARFI technology in evaluating effect of NAC for breast carcinoma were 85.7 % and 89.1% ,and the total efficiency was 71.7 %. Compared with the pathological evaluation, there was no statistically significant in the differences. Conclusion The ARFI technology provide quantitative elasticity measurements to make objective evaluation for the effect of NAC which has certain clinical application value.
出处 《济宁医学院学报》 2014年第4期260-262,共3页 Journal of Jining Medical University
基金 山东省教育厅资助项目(编号:J09LF26)
关键词 乳腺癌 新辅助化疗 弹性成像 超声 Breast carcinoma Neoadjuvant chemotherapy Acoustic radiation force impulse imaging Ultrasound
  • 相关文献

参考文献9

二级参考文献46

  • 1程琳,乔新民,杨德启,佟富中,周波,曹迎明,刘鹏,刘宏军,王殊,刘淼,张嘉庆.乳腺癌保乳手术治疗148例分析[J].中国微创外科杂志,2004,4(4):276-278. 被引量:43
  • 2沈镇宙,柳光宇,苏逢锡,何萍青,杨名添,施俊义,盛援,邹强,李亚芬.多西紫杉醇加表柔比星治疗局部晚期乳腺癌的多中心Ⅱ期临床研究[J].中华肿瘤杂志,2005,27(2):126-128. 被引量:56
  • 3宋艳利,王东.新辅助化疗对Ⅱ期乳腺癌的疗效观察[J].中国肿瘤临床,2007,34(7):411-412. 被引量:7
  • 4王殊,张嘉庆,乔新民,杨德启,佟富中.新辅助化疗后乳腺癌病理变化31例分析[J].中国妇产科临床杂志,2007,8(4):282-284. 被引量:7
  • 5[1]Fisher B, Mamounas EP,Preoperative chemotherapy: A model for studying the biology and therapy of primary breast cancer. J Clin Oncol,1995,13:537-540.
  • 6[2]Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res,1987,47:3889-3894.
  • 7[3]Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol, 1999,17: 3412-3417.
  • 8[4]Moliterni A, Tarenzi E, Capri G, et al. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin Oncol,1997,24(Suppl17) :10-14.
  • 9[5]Vlastos G, Mirza NQ, Lenert JT, et al. The feasibility of minimally invasive surgery for stage ⅡA,ⅡB,and ⅢA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer, 2000, 88:1417-1424.
  • 10[6]Fisher B, Guiduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res,1983,43:1488-1492.

共引文献92

同被引文献60

  • 1中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量:266
  • 2胡文娟,张蓓,潘玉林,谢蕴,刘维燕.磁共振灌注成像对局部进展期乳腺癌新辅助化疗疗效的评价[J].放射学实践,2011,26(1):25-29. 被引量:18
  • 3陶学伟,徐仁根,王索宇.乳腺癌钼靶摄影X线诊断[J].江西医药,2006,41(12):1024-1025. 被引量:4
  • 4邱龙华,顾雅佳.乳腺癌新辅助化疗的MRI评价[J].国外医学(临床放射学分册),2007,30(4):256-260. 被引量:10
  • 5Buchholz TA,Lehman CD,Harris JR,et al. Statement of the sci- concerning loeoregional treatments after preoperative chemotherapy for breast cancer:a National Cancer Institute confer- ence[J]. Journal of Clinical Oncoloav. 2008.26(5): 791-797.
  • 6Fisher ER,Wang J,Bryant J,et al. Pathobiology of preoperative chemotherapy:findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18[J]. Cancer,2002,95(4):681- 695.
  • 7Hafiz F ,Choudhury T,Kamal M,et aL The spectrum of pathological changes in breast cancer following neoadjuvant chemotherapy [J]. MMJ, 2014,23(2) : 272-280.
  • 8Keune JD,Jeffe DB,Schootman M,et al. Accuracy of ultrasonog- raphy and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer [J]. American Journal of Surgery,2010,199(4) :477-484.
  • 9Belli P, Costantini M, Malaspina C, et al. MRI accuracy in residu- al disease evaluation in breast cancer patients treated with neoad- juvant chemotherapy[J]. Clinical radiology, 2006,61(11) :946-953.
  • 10Pickles MD,Lowry M,Manton D],et al. Prognostic value of DCE- MRI in breast cancer .patients undergoing neoadjuvant chemother- apy:a comparison with traditional survival indicators [J]. European Radiology, 2015,25(4): 1097-1106.

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部